Antipsychotic treatment in child and adolescent first-episode psychosis: A longitudinal naturalistic approach

Journal of Child and Adolescent Psychopharmacology

Volumn 18, Issue 4, 2008, Pages 327-336

  Castro Fornieles, Josefina ^a,g   Parellada, Mara ^b   Soutullo, César A ^c   Baeza, Immaculada ^a   Gonzalez Pinto, Ana ^d   Graell, Montserrat ^e   Paya, Beatriz ^f   Moreno, Dolores ^b   De La Serna, Elena ^a   Arango, Celso ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADOLESCENT; AKATHISIA; ARTICLE; BIPOLAR DISORDER; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; DEPRESSION; DISABILITY ASSESSMENT SCHEDULE SCALE; DYSTONIA; FEMALE; GLOBAL ASSESSMENT OF FUNCTION SCALE; HUMAN; HYPERKINESIA; HYPOKINESIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MANIC PSYCHOSIS; MUSCLE RIGIDITY; NEGATIVE SYNDROME; PARESTHESIA; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SCHOOL CHILD; SEIZURE; SIDE EFFECT; TREMOR; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHILD; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 50949131939     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2007.0138     Document Type: Article

References (55)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington (DC): American Psychiatric Association, 1994.
2. Arango C, Parellada M, Moreno DM: Clinical effectiveness of new generation antipsychotics in adolescent patients. Eur Neuruopsychopharmacol 14:S471-479, 2004.
3. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J: Risperidone in adolescents with schizophrenia: An open pilot study. J Am Acad Child Adolesc Psychiat 3:694-700, 1997.
4. Asarnow JR, Tompson MC, McGrath EP: Annotation: Childhood-onset schizophrenia: Clinical and treatment issues. J Child Psychol Psychiatry 45:180-194, 2004.
5. Ballageer T, Malla A, Manchanda R, Takhar J, Haricharan R: Is adolescent-onset first-episode psychosis different from adult onset?. J Am Acad Child Adolesc Psychiatry 44:782-789, 2005.
6. Blanz B, Schmidt MH: Letter to editor, Clozapine for schizophrenia. J Am Acad Child Adolesc Psychiatry 32:223-224, 1993.
7. Bryden KE, Carrey NJ, Kutcher SP: Update and recommendations for the use of antipsychotics in early-onset psychoses. J Child Adolesc Psychopharmacol 11:113-130, 2001.
8. Castro-Fornieles J, Parellada MJ, Gonzalez-Pinto A, Moreno MD, Graell M, Baeza I, Otero S, Soutullo CA, Crespo-Facorro B, Ruiz-Sancho A, Desco M, Rojas-Corrales O, Patiño A, Carrasco-Marin E, Arango C and the CAFEPS group: The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. Schiz Res 91:226-237, 2007.
9. Correll J: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: A systematic review and pooled analysis of short-term trials. Am Acad Child Adolesc Psychiatry 46:687-700, 2007.
10. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM: A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 68:789-795, 2007.
11. Endicott J, Spitzer RL, Fleiss JL, Cohen J: The Global Assessment Scale. Arch Gen Psychiatry 33:766-777, 1976.
12. Findling RL, McNamara NK, Youngstrom EA, Branicky LA, Demeter CA, Schulz SC: A prospective, open-label trial of olanzapine in adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 42:170-175, 2003.
13. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A: Clinical drug monitoring in child and adolescent psychiatry: Side effects of atypical neuroleptics. J Child Adolesc Psychopharmacology 16:308-316, 2006.
14. Fleischhaker C, H Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A: Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 114:273-280, 2007.
15. Frazier JA, Gordon CT, McKenna K, Lenane MC, Rapoport JL:. An open trial of Clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 33:658-663, 1994.
16. Gothelf D, Apter A, Rediman J, Brand-Gothelf A, Bloch Y, Gal G: Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia. J Neural Transm 11:545-560, 2003.
17. Grcevich S: Comparative side effects of atypical antipsychotics in children and adolescents. Schizophr Res 49(suppl):284, 2001.
18. Grcevich SJ, Findling RL, Rowane WA, Friedman L, Schulz SC: Risperidone in the treatment of children and adolescents with schizophrenia: A retrospective study. J Child Adolesc Psychopharmacol 6:251-257, 1996.
19. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278-296, 1967.
20. Hollingshead AB, Redlich FC: Social Class and Mental Illness. New York, Wiley, 1958.
21. Janca A, Kastrup M, Katschnig H, Lopez-Ibor JJ Jr, Mezzich JE: The World Health Organization Short Disability Assessment Schedule (WHO DAS-S): A tool for the assessment of difficulties in selected areas of functioning of patients with mental disorders. Soc Psychiatry Psychiat Epidemiol 31:349-359, 1996.
22. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36(suppl):980-988, 1997.
23. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276, 1987.
24. Kranzler HN, Kester HM, Gerbino-Rosen G, Henderson IN, Youngerman J, Beauzile G, Ditkowsky K, Kumra S: Treatment-refractory schizophrenia in children and adolescents: An update on clozapine and other pharmacologic interventions. Child Adolesc Psychiatr Clin N Am 15:135-159, 2006.
25. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghbandrad J, Rapoport JL: Childhood-Onset Schizophrenia: A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53:1090-1097, 1996.
26. Kumra S, Jacobsen LK, Lennane M, Karp BI, Frazier JA, Smith AK, Bedwell J, Lee P, Malanga CJ, Hamburger S, Rapoport JL: Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry 37: 360-363, 1998.
27. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, Correll CU, Kane JM: Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison. Biol Psychiatry, published on line ahead of print, 2007.
28. Laita P, Cifuentes A, Doll A, Llorente C, Cortes I, Parellada M, Moreno D, Ruiz-Sancho A, Graell M, Arango C: Antipsychotic-related abnormal involuntary movements and metabolic and endocrine side effects in children and adolescents. J Child Adolesc Psychopharmacol 17:487-502, 2007.
29. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Dabis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Medicine 353:1209-1223, 2005.
30. Lingjaerde O, Ahlfors, UG, Bech P, Dencker SJ, Elgen K: UKU side effect rating scale. Acta Psychiatr Scand 76:7s-100s, 1987.
31. McConville BJ, Arvanitis LA, Thyrom PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE: Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate: An open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 61:252-260, 2000.
32. McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K: Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: An open-label extension trial. J Child Adolesc Psychopharmacol 13:75-82, 2003.
33. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RSE, Davis CE, Severe J, Hsiao JK for the CATIE Investigators: Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610, 2006.
34. Meighen KG, Shelton HM, McDougle CJ: Ziprasidone treatment of two adolescents with psychosis. J Child Adolesc Psychopharmacol 14:137-142, 2004.
35. Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R: Olanzapine treatment in chronic drug-resistant childhoodonset schizophrenia: An open-label study. J Child Adolesc Psychopharmacol 13:311-317, 2003.
36. Murphy BP, Chung Y, Park T, McGorry PD: Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schiz Res 88:5-25, 2006.
37. Olfson M, Blanco C, Liu L, Moreno C, Laje G: National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 63:679-685, 2006.
38. Peralta V, Cuesta M: Validación de la escala de los syndromes positivo y negativo (PANSS) en una muestra de esquizofrénicos españoles. [Validation of negative and positive syndrome scale (PANSS) in Spanish schizophrenic patients.] Actas Luso-Esp Neurol Psychiatr 22:171-177,1994.
39. Pool D, Bloom W, Mielke DH, Roniger Jr JJ, Gallant DM: A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Cur Ther Res 19:99-104,1976.
40. Ross RG, Novins D, Farley GK, Adler LE. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13:301-309, 2003.
41. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: Clinical experience. J Child Neurology 20:603-610, 2005.
42. Schmidt M, Blanz B, Dippe A, Koppe T, Lay B. Course of patients diagnosed as having schizophrenia during first episode occurring under age 18 years. Eur Arch Psychiatry Clin Neurosci 245:93-100, 1995.
43. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M: A study of quetiapine: Efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychoparmacol 11:415-424, 2001.
44. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenana M, Rapoport JL: Childhoodonset schizophrenia: A double-blind, randomized clozapineolanzapine comparison. Arch Gen Psychiatry 63:721-730, 2006.
45. Sholevar EH, Baron DA, Hardie TL: Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 10:69-78, 2000.
46. Siefen G, Remschmidt H: Results of treatment with clozapine in schizophrenic adolescents. Z Kinder Jugendpsychiatr 14:245-257, 1986.
47. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA: A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133-145, 2004.
48. Spencer EK, Campbell M: Children with schizophrenia: Díagnosis, phenomenology, and pharmacotherapy. Schiz Bull 20:713-725, 1994.
49. Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164:1547-1556, 2007.
50. Took KJ, Buck BL: The effect on weight of switching from risperidone to quetiapine in children and adolescents who experience excessive weight gain on risperidone. Schizophr Res 42(suppl):248, 2001.
51. Turetz M, Mozes T, Toren P, Chernauzan N, Yoran-Hegesh R, Mester R, Wittenberg N, Tyano S, Wizman A: An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry 170:507-510, 1997.
52. Ulloa RE, Ortiz S, Higuera F, Nogales I, Fresan A, Apiquian R, Cortes J, Arechavaleta B, Foulliux C, Martinez P, Hernandez L, Dominguez E, de la Peña F: Interrater reliability of the Spanish version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL). Actas Españolas Psiquiatria 34:36-40, 2006.
53. Volkmar FR: Childhood and adolescent psychosis: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 30:457-465, 1996.
54. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 133:429-435,1978.
55. Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S: Effectiveness, safety and tolerability of risperidone in adolescents with schizophrenia: An open label study. J Child Adolesc Psychopharmacol, 13:319-327, 2003.